Article Information
History
- June 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrew S. Mendiola1,2,*,†,
- Kaira A. Church2,*,
- Sandra M. Cardona2,3,
- Difernando Vanegas2,
- Shannon A. Garcia2,
- Wendy Macklin4,
- Sergio A. Lira5,
- Richard M. Ransohoff6,
- Erzsebet Kokovay7,8,
- Chin-Hsing Annie Lin2 and
- Astrid E. Cardona2,3
- 1Gladstone Institutes, San Francisco, California, 94158, USA
- 2Department of Biology, The University of Texas at San Antonio, San Antonio, TX 78249, USA
- 3South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA
- 4Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, CO 80045, USA
- 5Precision Immunology Institute Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- 6Third Rock Ventures, Boston, MA 02116, USA
- 7Cell Systems and Anatomy, UT-Health Science Center San Antonio, San Antonio TX 78229, USA
- 8Barshop Institute of Longevity and Aging Studies, San Antonio, TX 78245, USA
- ↵†Co-corresponding Authors: Email: andrew.mendiola{at}gladstone.ucsf.edu
Posted June 07, 2021.
Microglial CX3CR1I249/M280 variant limits neurogenesis and remyelination in cuprizone-induced multiple sclerosis model
